Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer

Human Pathology

Volumn 43, Issue 9, 2012, Pages 1363-1375

  Pierceall, William E ^a   Sprott, Kam M ^a   Heikkinen, Tuomas ^b   Heikkila, Paivi ^b   Alaparthi, Lakshmi ^a   Aittomaki, Kristiina ^b   Al Adhami, Mohammed ^a   Villegas Bergazzi, Vivian ^a   Meyer, Jane L ^a   Kutok, Jeffery L ^c   Bartkova, Jirina ^d   Bartek, Jiri ^d,e   Nevanlinna, Heli ^b   Weaver, David T ^a   Blomqvist, Carl ^b  

^a On Q ity Inc   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^e PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Anthracycline; Biomarker; Breast cancer; Genomic instability; Methotrexate; Personalized medicine; TOP2A

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; HELICASE; METHOTREXATE; TOPO2A PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; TISSUE MICROARRAY; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; FLUOROURACIL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATINS; METHOTREXATE; MIDDLE AGED; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84864282359     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.08.018     Document Type: Article

References (35)

1. K.A. Olaussen, A. Dunant, and P. Fouret DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy New Engl J Med 355 2006 983 991 (Pubitemid 44343542)
2. A. Chintamani, B.P. Jha, V. Bhandari, A. Bansal, S. Saxena, and D. Bhatnagar The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer Int Semin Surg Oncol 4 2007 5
3. K. Söderlund, L. Skoog, T. Fornander, and M.S. Askmalm The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer Radiother Oncol 84 2007 242 251 (Pubitemid 47371156)
4. T.D. Halazonetis, V.G. Gorgoulis, and J. Bartek An oncogene-induced DNA damage model for cancer development Science 319 2008 1352 1355 (Pubitemid 351354863)
5. J. Bartek, J. Bartkova, and J. Lukas DNA damage signalling guards against activated oncogenes and tumour progression Oncogene 26 2007 7773 7779 (Pubitemid 350242463)
6. S.P. Jackson, and J. Bartek The DNA-damage response in human biology and disease Nature 461 2009 1071 1078
7. T.A. Järvinen, M. Tanner, and V. Rantanen Amplification and deletion of topoisomerase II alpha associate with Erb-2 amplification and effect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer Am J Pathol 156 2000 839 847 (Pubitemid 30626942)
8. A. Di Leo, D. Gancberg, and D. Larsimont HER2 amplification and topoisomerase IIa gene aberrations as predictive markers in node-positive breast cancer patients randomly treated with either an anthracycline-based therapy or with cyclophosphamide, methotrexate and 5-fluorouracil Clin Cancer Res 8 2002 1107 1116 (Pubitemid 34517647)
9. A.S. Knoop, H. Knudsen, and E. Baislev Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive biomarkers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group J Clin Oncol 23 2005 7483 7490 (Pubitemid 46291811)
10. F.P. O'Malley, S. Chia, and D. Tu Topoisomerase II alpha and responsiveness of breast cancer to adjuvant therapy J Natl Cancer Inst 101 2009 644 650
11. K.A. Gunnarsdottir, M.B. Jensen, and D. Zahrieh CEF is superior to CMF for tumours with TOP2A alterations: a subpopulation treatment effect pattern plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D Br Cancer Res Treat 123 2010 163 169
12. J.M. Bartlett, A.F. Munro, and J.A. Dunn Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601) Lancet Oncology 3 2010 266 274
13. M.F. Press, G. Sauter, and M. Buyse Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based therapy J Clin Oncol 29 2010 859 867
14. G.E. Konecny, G. Pauletti, and M. Untch Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer Breast Canc Res Treat 120 2010 481 489
15. K. Kawachi, T. Sasaki, and A. Murakami The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant therapy Pathol Res Pract 206 2010 156 162
16. K. Aaltonen, C. Blomqvist, and R.M. Amini Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers Clin Cancer Res 14 2008 1976 1983 (Pubitemid 351551106)
17. L.C. Hautala, D. Greco, and R. Koistinen Glycodelin expression associates with differential tumour phenotype and outcome in sporadic and familial non-BRCA1/2 breast cancer patients Breast Cancer Res Treat 128 2011 85 95
18. O. Kilpivaara, J. Bartkova, and H. Eerola Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients Int J Cancer 113 2005 575 580 (Pubitemid 40038733)
19. C.W. Elston, and I.O. Ellis Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 1991 403 410
20. J. Woodcock-Mitchell, R. Eichner, W.G. Nelson, and T.T. Sun Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies J Cell Biol 95 1982 580 588 (Pubitemid 13215875)
21. R.E. Mueller, R.K. Parkes, I. Andrulis, and F.P. O'Malley Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast cancer samples Genes Chromo Canc 39 2004 288 297 (Pubitemid 38326310)
22. R. Tubbs, W.E. Barlow, and G.T. Budd Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status J Clin Oncol 27 2009 3881 3886
23. J. Bartkova, J. Tommiska, and L. Oplustilova Aberrations of the Mre11-Rad50-Nbs1 DNA damage sensor complex in human breast cancer: Mre11 as a candidate familial cancer-predisposing gene Mol Oncol 2 2008 296 316
24. C. Lukas, J. Bartkova, and L. Latella DNA damage-activated kinase Chk2 is independent of proliferation or differentiation, yet correlates with tissue biology Cancer Res 61 2001 4990 4993 (Pubitemid 32681525)
25. J.S. Coon, E. Marcus, and S. Gupta-Burt Amplification and overexpression of topoisomerase IIa predict response to anthracycline-based therapy in locally advanced breast cancer Clin Cancer Res 8 2002 1061 1067 (Pubitemid 35177356)
26. J.C. Brase, M. Schmidt, and T. Fischbach ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction Clin Canc Res 16 2010 2391 2401
27. M.N. Levine, V.H. Bramwell, and K.I. Pritchard Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 16 1998 2651 2658 (Pubitemid 28363028)
28. M.N. Levine, K.I. Pritchard, V.H. Bramwell, L.E. Shepherd, D. Tu, N. Paul National Cancer Institute of Canada Clinical Trials Group Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5 J Clin Oncol 23 2005 5166 5170 (Pubitemid 46224025)
29. C.J. Poole, H.M. Earl, and L. Hiller Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer N Engl J Med 355 2006 1851 1862 (Pubitemid 44664643)
30. K. Villman, E. Stahl, G. Liljegren, U. Tidefelt, and M.G. Karlsson Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas Mod Pathol 15 2002 486 491 (Pubitemid 34521397)
31. D. Branzei, and M. Foiani Maintaining genome stability at the replication fork Nat Rev Mol Cell Biol 11 2010 208 219
32. J. Bartkova, Z. Horejsi, and K. Koed DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis Nature 434 2005 864 870 (Pubitemid 40558993)
33. V.G. Gorgoulis, L.V. Vassiliou, and P. Karakaidos Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions Nature 434 2005 907 913 (Pubitemid 40559004)
34. J. Bartkova, N. Rezaei, and M. Liontos Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints Nature 444 2006 633 637 (Pubitemid 44864442)
35. R. DiMicco, M. Fumagalli, and A. Cicalese Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication Nature 444 2006 638 642 (Pubitemid 44864443)